Fujisawa, Japan

Tomohiro Seki

This inventor holds 8 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 5 EPO patents. Top assignees: Takeda Pharmaceutical Company Limited, Nippon Telegraph and Telephone Corporation, Tokyo Medical and Dental University. Active years: 1999-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tomohiro Seki. Retrieved from https://idiyas.com/inventor/tomohiro-seki-xqzfvycf

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 

% Patents Active = 100.0


 

Average Co-Inventor Count = 7.3

ph-index = 3

Forward Citations = 39(Granted Patents)


Location History:

  • Yokohama, JP (2010)
  • Fujisawa, JP (2020)
  • Kanagawa, JP (1999 - 2023)
  • Fujisawa Kanagawa, JP (2021 - 2023)

Company Filing History:


Years Active: 1999-2025

Loading Chart...
Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Innovations of Tomohiro Seki

Introduction

Tomohiro Seki is a prominent inventor based in Fujisawa, Kanagawa, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of nucleic acid agents and compounds with therapeutic potential. With a total of eight patents to his name, Seki's work is at the forefront of innovative medical solutions.

Latest Patents

One of Seki's latest patents is focused on a BBB-crossing lipid ligand of hetero nucleic acid. The objective of this invention is to provide a nucleic acid agent that can be efficiently delivered to the nervous system, especially the central nervous system, which is typically challenging due to the blood-brain barrier. This invention aims to produce an antisense effect on a target transcriptional product at the delivery site. The patent describes a double-stranded nucleic acid complex formed by annealing a first nucleic acid strand capable of hybridizing to part of a target transcriptional product, along with a second nucleic acid strand that is bound to tocopherol or an analog, cholesterol or an analog, or various alkyl or alkenyl groups.

Another significant patent involves methods of making a cyclic dinucleotide. This disclosure presents a compound with STING agonistic activity, which may be beneficial for the prophylaxis or treatment of STING-related diseases. The compound is represented by a specific formula, and its potential applications in medicine are noteworthy.

Career Highlights

Throughout his career, Tomohiro Seki has worked with notable companies, including Takeda Pharmaceutical Company Limited and Nippon Telegraph and Telephone Corporation. His experience in these organizations has contributed to his expertise in the field of biotechnology and pharmaceuticals.

Collaborations

Seki has collaborated with esteemed colleagues such as Yasuo Nakagawa and Kosuke Hidaka. These partnerships have likely enhanced his research and development efforts, leading to innovative solutions in his field.

Conclusion

Tomohiro Seki's contributions to biotechnology through his patents and collaborations highlight his role as a significant inventor in the industry. His work continues to pave the way for advancements in medical treatments and therapies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…